Microsoft, weight loss drug sales, and GSK profits surge

Business

In today’s episode, Ian King speaks with Dan Ives – managing director of the brokerage and advisory firm Wedbush Securities – to discuss Microsoft’s revenues and AI.

Ian Johnston, global pharmaceutical correspondent at the Financial Times, discusses sales of popular weight loss drug ‘Wegvoy’, made by Novo Nordisk – as they say their sales almost quadrupled last year.

And, Ian discusses GSK’s operating profit of £8.8bn for 2023 with strong selling medicines including its HIV and shingles medication.

Articles You May Like

Myanmar frees more than 6,000 prisoners to mark anniversary
England cricket rejects call for Afghanistan boycott over Taliban assault on women’s rights
Soldier who blew up Tesla at Trump hotel left notes saying explosion should be ‘wake up call’
Cruz Hewitt, son of Aussie great, loses in qualifying
Tesla issues recall on over 200,000 for the self-driving computer failure